It was recently reported that oral administration of titanium dioxide (TiO2) nanoparticles aggravated the severity of IBD through a mechanism involving the activation of the NLRP3 inflammasome in DSS-induced colitis mice or UC patents (108). The gene discussed is NLRP3; the disease is colitis.